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Summary
Background A rising incidence and high mortality were found for bullous pem-
phigoid (BP) over a decade ago in the UK. Updated estimates of its epidemiology
are required to understand the healthcare needs of an ageing population.
Objectives To determine the incidence, prevalence and mortality rates of BP in Eng-
land from 1998 to 2017.
Methods We conducted a cohort study of longitudinal electronic health records
using the Clinical Practice Research Datalink and linked Hospital Episode Statistics.
Incidence was calculated per 100 000 person-years and annual point prevalence
per 100 000 people. Multivariate analysis was used to determine incidence rate
ratios by sociodemographic factors. Mortality was examined in an age-, sex- and
practice-matched cohort, using linked Office of National Statistics death records.
Hazard ratios (HRs) were stratified by matched set.
Results The incidence was 763 [95% confidence interval (CI) 735–793] per
100 000 person-years and rose with increasing age, particularly for elderly men.
The annual increase in incidence was 09% (95% CI 02–17). The prevalence
almost doubled over the observation period, reaching 4799 (95% CI 4309–
5346) per 100 000 people and 14124 (95% CI 12555–15887) per 100 000
people over the age of 60 years. The risk of all-cause mortality was highest in
the 2 years after diagnosis (HR 296; 95% CI 268–326) and remained raised
thereafter (HR 154; 95% CI 136–174).
Conclusions We report a modest increase in the incidence rate of BP, but show that
the burden of disease in the elderly population is considerable. Mortality is high,
particularly in the first 2 years after diagnosis.
What is already known about this topic?
• Bullous pemphigoid (BP) is a blistering skin disorder which typically affects the
elderly.
• BP poses a high burden on affected patients and has significant healthcare costs.
• The burden of disease in the UK was estimated over a decade ago and found to
have a rising incidence and high mortality.
What does this study add?
• The incidence of BP in England was 763 (95% CI 735–793) per 100 000 per-
son-years between 1998 and 2017.
• The burden of BP in the elderly population is substantial and it should not be con-
sidered a rare disease in these age groups.
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• The risk of death was almost three times higher in the first 2 years after a diagnosis
of BP compared with people without the disease and remained raised thereafter.
Bullous pemphigoid (BP) is a rare autoimmune disease, char-
acterized by blistering of the skin. It is predominantly a dis-
ease of the elderly, and is associated with high morbidity,
mortality and significant healthcare costs.1,2 A previous study
of BP in the UK estimated that the incidence was increasing
by 17% per annum between 1996 and 2006.3 However, this
work was conducted over a decade ago and included only
patients identified in primary care. More severe cases whose
diagnosis was not returned to their general practitioner (GP),
potentially because they died in hospital shortly after being
diagnosed, would not have been captured. An updated esti-
mate is required to quantify the burden of disease in England,
which may be an important consideration when assessing the
healthcare needs of an ageing population.
Routinely collected electronic healthcare records are valuable
for examining a rare disease like BP, because of the availability
of data on a large number of patients that are broadly repre-
sentative of the UK population. Patients with BP can be identi-
fied using a validated method and code list with a positive
predictive value of 932% [95% confidence interval (CI)
913–948).4 The incidence and prevalence rates can be deter-
mined with high precision, while longitudinal follow-up
allows long-term outcomes, such as death, to be examined.
The aim of the present work was to determine the incidence,




Incidence and prevalence were examined using a retrospective
cohort. An age-, sex- and practice-matched longitudinal cohort
was used to compare the mortality of BP with the general
population. We followed RECORD guidelines for the reporting
of studies conducted using observational routinely collected
health data.5
Data sources
Clinical Practice Research Datalink
The CPRD GOLD is a longitudinal database of UK general
practices using the Vision software system. It contains anon-
ymized healthcare records for approximately 17 million
patients, with a current coverage of approximately 27 million
(4%) of the UK population. Routinely collected clinical data
generated from consultations, hospital discharges or specialist
clinic letters are recorded using Read codes.6 Diagnoses of BP
are predominantly made in secondary care, but are subse-
quently returned to GPs and entered into primary care
records.
The data in the GPRD have repeatedly been shown to be of
good research quality.7 At practice level, participating prac-
tices are assigned an ‘up-to-standard’ date on completion of
regular audits confirming data quality. At the patient level,
records are assessed and patients are deemed ‘acceptable’ if
data checks indicate that their record meets prespecified
quality standards.
Linked data
Approximately 75% of English practices, covering more than
10 million patients, have consented to provide patient-level
information from linked resources.8 The individual-level
linked sources used in this study were Hospital Episode Statis-
tics (HES) admitted patient care data and Office for National
Statistics (ONS) death registration data. HES admitted patient
care contains diagnoses for each hospitalization episode, coded
using the International Classification of Diseases version 10
(ICD-10).9,10 Death registration data contain the official date
of death.
Study population
Adult men and women registered with 410 HES-linked gen-
eral practices in England during the period of 1 January 1998
to 31 December 2017 were included. Patients were eligible
from the date their practice was deemed to be contributing
up-to-standard data and their record was verified as ‘accept-
able’ research quality.
Outcomes
For incidence and prevalence, the outcome was a diagnosis of
BP in the CPRD or HES. The date of death was the outcome
for the all-cause mortality analyses.
Case definition of bullous pemphigoid
A diagnosis of BP is usually made on referral to a dermatology
department, where patients undergo clinical examination and
laboratory investigations, usually a skin biopsy for histology
and direct immunofluorescence. The diagnosis is consequently
communicated to primary care, where it is entered in the
CPRD using Read codes, or to the person’s inpatient records,
where it is entered in the HES admitted patient care records
using ICD-10 codes.
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People with BP were adult patients with a diagnostic code
for BP in the CPRD or HES. An algorithm was applied to the
CPRD to identify patients with Read codes for BP (M145,
‘bullous pemphigoid’; M14500, ‘pemphigoid’; or M145z00,
‘pemphigoid not otherwise specified’).4 A similar algorithm,
using ICD-10 diagnostic codes, was applied to HES admitted
patient care data (L120, ‘bullous pemphigoid’; or L129,
‘pemphigoid, unspecified’). The index date of diagnosis for
people with BP was the first date of occurrence of the Read or
ICD-10 code generated from the algorithm.
Incident diagnoses were those with an index date at least 1
year after their current registration date with their GP. The 1-
year lag period was imposed to minimize the risk of prevalent
cases being identified as incident ones.11 Prevalent diagnoses
were those with a record of BP at any point before the end of
the observation period.
Matched disease-free individuals
Up to four disease-free unexposed individuals were selected
randomly for each case and matched by age (within 1 year of
date of birth), sex and general practice. They were assigned
an index date, which was the date of diagnosis of BP of the
case they were matched to. The matched disease-free individu-
als had to be alive and contributing data at the time of the
index date.
Observation period
The observation period commenced on the latest of (i) 1 Jan-
uary 1998, (ii) the date the patient registered with their cur-
rent practice, (iii) the practice’s up-to-standard date, or (iv)
the patient’s 18th birthday.
The observation period terminated on the earliest of (i) 31
December 2017, (ii) the date of death, (iii) the date the
patient left the practice, (iv) the practice’s last data collection




The incidence rates per 100 000 person-years overall and by
age (10-year bands), calendar period (3-year bands), sex, eth-
nicity, region and index of multiple deprivation were calcu-
lated. Poisson regression was used to determine incidence rate
ratios (RRs) for each sociodemographic factor. For the unor-
dered categorical factors, region and ethnicity, the group with
the most person-years of follow-up was chosen as the refer-
ence category. Multivariate regression was used to adjust for
age, sex and calendar period. A post hoc examination of the
interaction between age and sex, adjusted for calendar period,
was conducted.
The crude and age- and sex-adjusted annual changes in
incidence were determined over the 20-year observation per-
iod. The crude incidence rate for each calendar year, with
direct standardization to the European Standard Population of
2013, was determined.
Annual point prevalence
The number of individuals with BP contributing data on 31
July of each calendar year was divided by the total number of
adults alive and contributing data at the same point in time.
Mortality
People with BP and their matched disease-free individuals
were followed from their index date and all deaths in the
cohort were identified. Crude mortality rates were calculated
per 1000 person-years. Kaplan–Meier techniques were used to
determine 1-year mortality and median survival time. All-
cause mortality in people with vs. without BP was compared
using Cox proportional hazards regression stratified by
matched set to account for age, sex, general practice and cal-
endar period. The proportional hazards assumption, tested
using Schoenfeld’s residual, was violated. The observation per-
iod was therefore divided into two follow-up periods: within
2 years and 2 years or more after the index date.
Study size
This was a population-based cohort study that used all avail-
able data. Assuming only one matched disease-free individual
was found per patient with BP, this study would have > 90%
power to detect a HR of 21 or greater at the 5% significance
level.3
Sensitivity analyses
The incidence, prevalence and mortality of BP in the UK were
established using all primary care data available in the CPRD,
irrespective of linkages. The results were compared with the
primary analyses, which included only patients registered with
HES-linked practices. Incidence RRs for ethnicity were deter-
mined only after 2006 as ethnicity data were more poorly
recorded for people who registered with the CPRD prior to
this.12
Unless otherwise specified, the P-values presented were
obtained from the likelihood ratio test and P < 005 was con-
sidered statistically significant. Analyses were conducted with
Stata 16 (2019; StataCorp LLC, College Station, TX, USA).
Ethical approval
The present study was approved by the Independent Scientific
Advisory Committee for the CPRD (ISAC protocol no
18_224).
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Results
Study population
There were 2658 incident individuals with BP identified dur-
ing the observation period: 2468 from English HES-linked
general practices in the CPRD (Figure 1) and an additional
190 individuals with a diagnosis of BP only in their HES
records. Median age at presentation was 81 (interquartile
range 72–87) years and 1497 (563%) of patients were
women.
Incidence
The pooled incidence rate over the 20-year period was 763
(95% CI 735–793) per 100 000 person-years (Table 1). The
crude incidence rate was 25% higher in women (RR 125,
95% CI 116–135), but after adjustment for age and calendar
period, the incidence rates were 13% lower in women (RR
087, 95% CI 080–094) than men. Incidence rates rose dra-
matically with age, such that the highest rates were recorded
in patients over 90 years. The increase in incidence in older
age groups was more marked for men than women (P-value
for interaction < 0001, Figure 2). After adjustment for age,
sex and calendar period, rates were highest in those of Asian
ethnicity and lowest in those of unknown ethnicity compared
to whites, but ethnicity data were missing in 26% of the
whole study population. Incidence varied by geographic
region, but not by level of deprivation.
Between 1998 and 2017, incidence increased by 12% (RR
1012; 95% CI 1005–1020; P = 0002) per calendar year.
After adjustment for age and sex, the estimated annual
increase in incidence was 09% (RR 1009; 95% CI 1002–
1017; P = 0016). Overall increase in incidence over the 20-
year study period (2017 vs. 1998) was 164% after adjust-
ment for age and sex (RR 1164; 95% CI 0805–1684; P =
0420). Annual incidence rates, calculated by direct standard-
ization to the European Standard Population, are illustrated in
Figure S1 (see Supporting Information).
Prevalence
The prevalence of BP was 2682 (95% CI 2383–3019) per
100 000 people in 1998 and increased to 4799 (95% CI
4309–5346) per 100 000 in 2017 (Figure 3). The most
recent estimate of the prevalence of BP in those aged over 60
years was 14124 (95% CI 12555–15887) per 100 000 peo-
ple in 2017. In the over-80s, the prevalence was 37502
(95% CI 32031–43904) per 100 000.
Mortality
The cohort included 2639 people with BP and 10 463
matched disease-free individuals (details provided in Support-
ing Information; Text S1). Within the cohort 1237 deaths
occurred in the individuals with BP and 3427 in those
without, equating to a crude mortality rate (per 1000 person-
years) of 13882 (95% CI 13130–14678) for people with
BP and 7456 (95% CI 7211–7710) for people without
(Table 2). The median survival time was 493 years for people
with BP and 927 years for people without (Figure 4). The 1-
year mortality for BP was 2036% (95% CI 1882–2200) and
703% (95% CI 654–755) for disease-free individuals.
After stratifying by matched set to account for age, sex and
general practice, the HR was 296 (95% CI 268–326) in the
first 2 years and 154 (95% CI 136–174) thereafter
(Table 2).
Sensitivity analyses
All results were confirmed in sensitivity analyses using patients
from all of the CPRD compared with the main analysis, which
examined HES-linked practices only (Texts S2–S4, Figures S2,
S3, Tables S1, S2; see Supporting Information).
Discussion
Our main findings are as follows. The incidence of BP during
the 20-year observation period was 763 (95% CI 735–793)
per 100 000 person-years. The incidence was highest in the
elderly, particularly in elderly men. Between 1998 and 2017,
the incidence of BP increased by 09% (95% CI 02–17) per
calendar year and the prevalence almost doubled from 2682
(95% CI 2383–3019) per 100 000 people in 1998 to 4799
(95% CI 4309–5346) per 100 000 people in 2017. Using
the European definition of a rare disease (prevalence < 50 per
100 000 people),13 we have for the first time shown that BP
is not a rare disease in the elderly (≥ 60 years).
The risk of death within 2 years of diagnosis was almost
three times higher in patients with BP than in matched dis-
ease-free individuals (HR 296, 95% CI 268–326). The mor-
tality remained raised throughout the remainder of the
observation period (HR 154, 95% CI 136–174).
There are comparisons that can be made with other studies.
An increasing incidence of BP has previously been reported in
the UK using data from The Health Improvement Network
(THIN) up to 2006.3 The current data show a more modest
increase in incidence over time, but a higher incidence rate
across the whole observation period. The reasons for these dif-
ferences are likely multifactorial, although largely driven by
differences between the databases used. Significantly lower
incidence rates have been reported for venous leg ulcers in
THIN compared with the General Practice Research Database
(the predecessor of CPRD) using data collected prior to
2000.14 The low incidence rate of BP observed using THIN,
particularly prior to 1998, may be artefactual and could
explain why a more dramatic increase in incidence over time
was found. Other factors that may explain the discrepancy
include small differences in either the numerator or denomi-
nator between the present and the earlier study. For example,
the present study used an algorithm to identify patients and
included patients that had records of BP in HES, but not
© 2020 The Authors. British Journal of Dermatology
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CPRD. Nevertheless, the absolute difference in incidence
between the studies remains small and reduces over time.
Our incidence results are similar to those reported recently
in Sweden.15 Using the National Patient Register the authors
reported an incidence of 71 (95% CI 65–77) per 100 000
person-years.15 In contrast, studies conducted elsewhere in the
world report lower results (Table S3; see Supporting Informa-
tion).3,15–28 This may be due to underlying differences in risk
between populations or because of differences in methods.
For example, other studies generally present rates for the pop-
ulation including children, who are rarely affected. In
addition, other studies are generally smaller, hospital based
and may not achieve complete capture of all cases within the
defined denominator as patients managed in primary care or
referred to other dermatology centres outside the geographical
boundaries of the study are often missed.
The 1-year mortality of 2036% in the present study is sim-
ilar to previous estimates from the UK. Between 1996 and
2006, the 1-year mortality in the UK using THIN was 19%
(95% CI 162–218).3 Between 1991 and 2001 the 1-year
mortality of the 83 incident cases identified from the Pathol-
ogy and Immunology database of a single referral centre in
Figure 1 Algorithm used to identify incident adult individuals with bullous pemphigoid in the Clinical Practice Research Datalink (CPRD) between
January 1998 and December 2017.
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North-east Scotland was 25%.23 A recent meta-analysis esti-
mated the pooled 1-year mortality rate in European popula-
tions to be 267% (95% CI 222–312), although the
heterogeneity between studies was large.28 Survival in the first
year after diagnosis appears marginally better in England than
in the rest of Europe, but worse than the USA (151%, 95%
CI 79–223). Such differences in mortality could be explained
by differences between populations, methods of case and out-
come ascertainment, temporal trends, or true differences in
the mortality between nations.
The strengths of this study include a large sample size, a
population that is representative of the UK general population,
use of a validated approach to identify cases, accurate record-
ing of death dates, and using linked primary and secondary
care data to get a more comprehensive coverage of cases.
Using routinely recorded data on a population level makes this
study less susceptible to selection bias.
Case ascertainment is a limitation as it is reliant on the
presence of clinical codes indicative of BP. Inaccurate record-
ing may have affected the estimates. We know from previous
Table 1 Univariate and multivariate analysis of incidence of bullous pemphigoid in Hospital Episode Statistics-linked general practices and hospital
inpatient records in England per 100 000 person-years
Variable Person-years Events Incidence rate (CI) Crude RR (CI) P-value
Mutually adjusted
incidence RRs (CI) P-value
Pooled 34 825 210 2658 763 (735–793) – –
Sex < 0001 < 0001
Male 17 171 950 1161 676 (638–716) 100 100
Female 17 653 250 1497 848 (806–892) 125 (116–135) 087 (080–094)
Age group (years) < 0001a < 0001a
< 60 24 467 650 254 104 (092–117) 100 100
60–69 4 765 380 264 554 (491–625) 534 (449–634) 534 (449–634)
70–79 3 423 240 662 1934 (1792–2087) 1863 (1612–2153) 1879 (1626–2172)
80–89 1 812 280 1074 5926 (5582–6292) 5709 (4979–6545) 5812 (5067–6667)
≥ 90 356 660 404 11327 (10275–12488) 10912 (9327–12766) 11288 (9636–13223)
Calendar year(years) 0007a 0049a
1998–2000 3 702 250 247 667 (589–756) 100 100
2001–2003 5 543 890 405 731 (663–805) 110 (094–128) 107 (091–126)
2004–2006 6 288 600 470 747 (683–818) 112 (096–131) 109 (094–128)
2007–2009 6 605 740 508 769 (705–839) 115 (099–134) 112 (096–130)
2010–2012 6 369 500 534 838 (770–913) 126 (108–146) 120 (103–140)
2013–2015 4 745 980 363 765 (690–848) 115 (098–135) 108 (092–127)
2016–2017 1 569 240 131 835 (703–991) 125 (101–155) 121 (098–150)
Ethnicity < 0001 < 0001
White 23 950 960 2318 968 (929–1008) 100 100
Blackb 484 490 14 289 (171–488) 030 (018–051) < 0001 080 (048–136) 0415
Asianb 965 200 47 487 (366–648) 050 (038–067) < 0001 137 (103–184) 0033
Otherb 418 380 23 550 (365–827) 057 (038–086) 0007 122 (081–184) 0347
Unknownb 9 006 180 256 284 (252–321) 029 (026–033) < 0001 063 (055–072) < 0001
Region < 0001 0020
North West 5 374 400 359 668 (602–741) 100 100
North East 799 330 43 538 (399–725) 081 (059–111) 081 (059–111)
Yorkshire &
The Humber
1 402 950 100 713 (586–867) 107 (086–133) 102 (082–128)
East Midlands 1 052 510 65 618 (484–788) 093 (071–120) 095 (073–124)
West Midlands 4 254 880 307 722 (645–807) 108 (093–126) 099 (085–115)
East of England 4 007 770 316 789 (706–880) 118 (102–137) 112 (096–130)
South West 4 355 830 430 987 (898–1085) 148 (129–170) 120 (104–138)
South Central 4 543 990 377 830 (750–918) 124 (108–144) 114 (099–132)
London 4 352 770 308 708 (633–791) 106 (091–123) 115 (099–134)
South East Coast 4 680 780 353 754 (679–837) 113 (098–131) 099 (085–114)
Deprivation 0005* 0208*
1 8 312 070 657 790 (732–853) 100 100
2 7 702 910 601 780 (720–845) 099 (088–110) 094 (084–105)
3 7 260 820 610 840 (776–910) 106 (095–119) 102 (091–114)
4 6 272 660 438 698 (636–767) 088 (078–100) 091 (080–102)
5 5 276 750 352 667 (601–741) 084 (074–096) 093 (081–106)
aLR test for trend; bWald’s test; all other P-values are from LR test. Mutually adjusted model is adjusted for age, sex and calendar year. CI,
confidence interval; HES, Hospital Episode Statistics; LR, likelihood-ratio test; RR, rate ratio
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021) 184, pp68–77
Incidence, prevalence and mortality of BP in England, Persson et al. 73
work that a small proportion of those identified with BP
codes are likely to have other diagnoses, such as mucous
membrane pemphigoid.4 Inversely, some patients with BP
may be missed as they are coded as having pemphigus vul-
garis. However, the positive predictive value of the BP codes
in this study is 93%, supporting our conclusions. Addition-
ally, it is difficult to interpret findings related to ethnicity
due to poor recording in those registered prior to 2006.
Finally, our work has assumed that once a patient has devel-
oped BP they remain a prevalent case until the end of fol-
low-up. In reality, patients may enter remission or become
disease-free, and the true prevalence of BP may be more
conservative than that presented.
The possible explanations for our findings follow here. The
incidence of BP rises with increasing age, which may reflect
an aetiology related to the biological process of ageing. This
effect was more marked in men. An alternative explanation
may be the age-related rise in prevalence of diseases associated
with the development of BP, such as dementia and Parkinson’s
disease.30,31 Alternatively, the relationship may reflect increas-
ing use of drugs that induce BP in the elderly population.
Variation in the incidence of BP was also observed between
Figure 2 Crude incidence rate of bullous pemphigoid in English Hospital Episode Statistics-linked general practices and hospital inpatient records
per 100 000 person-years per age category. Rates shown separately for men and women, with upper and lower limits of 95% confidence
intervals.
Figure 3 Point prevalence of bullous pemphigoid on 31 July of each calendar year in English Hospital Episode Statistics-linked general practices,
per 100 000 people. Prevalence rates shown for all adults and for people aged over 60 years, with shading indicating the upper and lower limits
of the 95% CI.
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021) 184, pp68–77
74 Incidence, prevalence and mortality of BP in England, Persson et al.
ethnic groups and geographic regions. The antidiabetic drug
dipeptidyl peptidase-4 inhibitor (DPP-4i) is associated with an
approximate doubling of the risk of BP32–36 and the increased
risk in Asians, compared with the white ethnic group, may
partly relate to the increased levels of diabetes in this ethnic
group. The rising trend for prescriptions of DPP-4i for dia-
betes throughout the study period may also contribute to the
increased incidence observed.37,38 Regional differences could
point to environmental factors, perhaps to differences in
incidence between urban and rural communities,18 or could
be due to differences in the prescribing patterns or awareness
of BP in the medical communities. The rising prevalence of BP
may be a result of the increasing incidence of the disease or
may reflect that the English population is living longer.39
Alternatively, it may be that the prevalence nearer the date of
database inception may be underestimated. People with diag-
noses prior to the inception of CPRD may not have had the
disease entered retrospectively into their electronic records.
Table 2 Hazard ratios (HRs) for death, stratified by matched set, comparing patients with bullous pemphigoid and matched disease-free people
from Hospital Episode Statistics-linked general practices and hospital inpatient records in England. Mortality rates are presented per 1000 person-
years
Variable Person-years Events Mortality rate (95% CI) Stratified HRa (95% CI) P-value
Pooledb
Controls 45 9615 3427 7456 (7211–7710) –
Cases 89107 1237 13882 (13130–14678)
< 2 years
Controls 17 3745 1270 7310 (6918–7723) 100 < 0001
Cases 37590 734 19526 (18164–20991) 296 (268–326)
≥ 2 years
Controls 28 5780 2157 7545 (7234–7871) 100 < 0001
Cases 51517 503 9764 (8947–10655) 154 (136–174)
aHR stratified by matched set to account for age, sex, general practice and calendar period; bstratified HR not calculated for the pooled fol-
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Figure 4 Kaplan–Meier curve for patients with and without bullous pemphigoid, showing mortality over time since index date and number of
patients remaining in the study.
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In terms of possible clinical implications of our findings,
healthcare professionals should be made aware that BP is not a
rare disease in the elderly. A greater awareness of the disease
will hopefully reduce diagnostic delay. The mortality risk from
BP has remained largely unchanged since it was last examined
over a decade ago. Improved management, a better under-
standing of the aetiology, and examination of the causes of
death in BP are still required.
In conclusion, BP is a rising concern for the ageing popula-
tion of England. In the elderly population, it should no longer
be considered a rare disease. Its incidence increases with age
and it is associated with almost a three times greater chance of
death in the first 2 years after diagnosis compared with dis-
ease-free individuals. The increased burden of disease, particu-
larly in the elderly, requires earlier diagnosis, improved
treatment and better understanding of the aetiology.
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